How does Onivyde work?
Onivyde (irinotecan liposome injection) is a topoisomerase I inhibitor. It works by interfering with a specific enzyme that cancer cells need to divide and grow [1]. By blocking this enzyme, Onivyde helps to slow or stop the growth of tumors [1].
What kind of cancer is Onivyde used for?
Onivyde is indicated for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [1].
How is Onivyde administered?
Onivyde is given intravenously (through an IV) [1].
What are the common side effects of Onivyde?
Common side effects reported by patients taking Onivyde include diarrhea, fatigue, nausea, decreased appetite, and vomiting [1]. Severe side effects can include neutropenia (low white blood cell count), severe diarrhea, and hypersensitivity reactions [1].
When did Onivyde receive FDA approval?
Onivyde was approved by the U.S. Food and Drug Administration (FDA) in October 2015 [1].
Who makes Onivyde?
Ipsen Biopharmaceuticals, Inc. is the manufacturer of Onivyde [1].
How does Onivyde's liposomal formulation affect its action?
The liposomal formulation encapsulates irinotecan within tiny fat bubbles. This delivery method can alter how the drug is distributed in the body, potentially leading to a different side effect profile or a sustained release of the active drug compared to non-liposomal irinotecan [1]. This formulation is designed to target tumor tissue more effectively.
What is the typical treatment regimen for Onivyde?
Onivyde is typically administered in combination with fluorouracil and leucovorin [1]. The dosage and schedule are determined by a healthcare professional based on the patient's condition and response to treatment.
What clinical trials have been conducted for Onivyde?
The FDA approval of Onivyde was based on a Phase 3 clinical trial, known as the NAPOLI-1 study, which demonstrated improved overall survival in patients with metastatic pancreatic adenocarcinoma whose disease had progressed after gemcitabine-based therapy [1].
Are there any patent protections for Onivyde?
Drug patents for Onivyde and its active ingredient, irinotecan, are managed by the manufacturer. Information regarding specific patent expirations and potential generic entry can be found through resources like DrugPatentWatch.com [2].
What are the alternatives to Onivyde for pancreatic cancer?
Treatment options for pancreatic cancer are diverse and depend on the stage of the disease. For metastatic pancreatic adenocarcinoma that has progressed, alternatives might include other chemotherapy regimens, targeted therapies, or immunotherapy, often determined through clinical trials or based on physician recommendations and patient-specific factors.